Subject Index

Adeno-associated virus, gene therapy vectors for Parkinson's disease 388, 389
Adenovirus vectors, gene therapy for Parkinson's disease 388

Ansa
  lenticularis, anatomy 22
  peduncularis, anatomy 24, 25

Atlas, development 3–5, 8

Baclofen, intrathecal
dystonia treatment 373, 374
  limitations 372
  rationale 372
  spasticity treatment outcomes 339, 340, 372, 373
  spinal cord distribution 372, 373

Ballismus
definition 42
  pathophysiology 60, 61

Barona Index 267

Basal ganglia
cortical circuits 31, 32, 119–122
dopaminergic pathways 26, 27, 29, 33
external ganglia projections 48
forebrain bundles
  ansa lenticularis 22
  ansa peduncularis 24, 25
  lenticular fasciculus 22–24
  medial forebrain bundle 25, 26
  subthalamic fasciculus
  pallidosubthalamic fibers 24
  subthalamopallidal fibers 24
thalamic fasciculus 24
  functions 33, 34
  lesion studies of motor functions 34
  motor circuit in monkeys 58, 59

Brain atlases, development 3–5, 8
Botulinum toxin type A, spasmodic torticollis type A treatment 303, 304
Brain-derived neurotrophic factor
  Parkinson's disease treatment 376, 377

Cerebral palsy, spasticity treatment in children 347

Chorea
definition 42
  pathophysiology 60, 61

Ciliary neurotrophic factor, Huntington's disease therapy 377
Computed tomography
certainty in brain nuclei identification 132
evaluation of movement disorder surgery patients 83, 92, 249
non-microelectrode recording-guided pallidotomy with magnetic resonance imaging 132, 133, 135

Core Assessment Program for Intracerebral Transplantation 79, 85

Deep brain stimulation, see also Globus pallidus, Subthalamic nucleus stimulation, Thalamic deep brain stimulation advantages and limitations 233, 234
complication avoidance 252, 253
lesioning comparison 227–232
mechanism of action
  high-frequency stimulation 237, 243
  single stimuli 236, 237, 243
  positron emission tomography applications 364–366
targets and indications 253
Dopamine
  biosynthetic genes for gene therapy 381–384, 390, 391
  receptor, antagonism and dystonia
  induction 45
Dorsal root entry zone, spasticity treatment
with surgery 344–346
Drug-induced dyskinesia
  pathophysiology 43, 44
  problems with models 70–73
Dyskinesia
  models, see 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine
  pathophysiology 60–63
  subthalamic nucleus stimulation induction 217
Dystonia
  cervical dystonia, see Torticollis
classification and genetics
dystonia-plus syndromes 281
  heredodegenerative 281
  primary 280
  secondary 281
definition 42
drug therapy 279, 291
  intrathecal baclofen therapy 373, 374
  pathophysiology 44–47, 121, 281, 282
  prevalence 279
  surgical management
  overview 282, 283, 292
  pallidotomy 287–291
  thalamotomy 283–287, 291, 292
Electromyography, spasmodic torticollis 300, 301, 303
Essential tremor
  thalamic deep brain stimulation electrode placement 184–186
  frame placement 183
  macroelectrode stimulation 183
  outcomes 186
  patient selection 182
  preoperative preparation 182, 183
  target localization 183, 184
  Vim thalamotomy 173
Fetal tissue transplantation, see Neural transplantation, Parkinson’s disease
Frame
  application and alignment 93, 94, 183
  complications 248
Gamma knife surgery
  complications 276
  limitations in movement disorder surgery 252
  outcomes
  Parkinson’s disease 275, 276
  stroke-related tremor 275, 276
  patient selection 277, 278
  radiosurgical technique 274, 275, 277
target
  localization 273, 274, 278
  selection 272, 273, 278
Gene therapy, Parkinson’s disease
  ex vivo approaches
    advantages and limitations 384
    immortalized cell lines 382, 383
    overview 381, 382
    primary cultures 383, 384
gene targets 381–384, 390, 391
  in vivo systems
    adeno-associated virus vectors 388, 389
    adenovirus vectors 388
    advantages 385
    herpes simplex virus-1 vectors
cell culture studies 386, 387
    rat model studies 387
types 385–388
  overview 385
  limitations 390, 391
Glial-derived neurotrophic factor
  Parkinson’s disease treatment 377
Subject Index 397
Globus pallidus, see also Pallidotomy
bicuculline inhibition 65
deep brain stimulation of internal segment
clinical assessment 149
complications 258, 259
high-frequency stimulation effects 242
implants 41, 42
indications 154
mechanism of action 240, 241
outcomes 151–153
pallidotomy comparison 228–230
patient selection 149
positron emission tomography
applications 365, 366
rationale 148, 149
single stimulus effects 242
surgical technique 149, 151
dopaminergic pathways 26, 27, 29
dystonia role 281, 282
fiber systems 22–27, 29
inactivation and movement disorder
improvement 34, 38, 40
internal segment hyperactivity in
Parkinson's disease 21, 34, 59,
119, 149
lesioning 40, 91, 120
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine model findings 59–65, 67–74
muscimol inhibition 374–376
pathophysiology
drug-induced dyskinesia 43, 44
dystonia 44–47
hemiballism 43
Huntington's disease 43
tremor role 38, 39
Hemiballism, pathophysiology 43, 121
Herpes simplex virus-1, gene therapy
vectors for Parkinson's disease
cell culture studies 386, 387
rat model studies 387
types 385–388
High-frequency stimulation, see Deep brain stimulation
Hoehn & Yahr staging 82, 85, 124, 141
Horsley-Clarke apparatus, development
2, 3
Huntington's disease
neurotrophic factor therapy 377
pathophysiology 43
Hyponia, subthalamic nucleus
stimulation induction 217, 218
Idiopathic torsion dystonia, positron emission tomography activation studies
360, 361
Intradural rhizotomy, spasmodic torticollis
treatment
anatomy 315, 316
complications 321, 322
historical perspective 313, 314
outcomes 316–320, 323
technique 315, 316
Intraoperative monitoring, see also Microelectrode recording
history of recording 6, 10, 12
somatosensory evoked potentials 99
visual evoked potentials 99, 101
Intrathecal therapy
baclofen, see Baclofen, intrathecal
muscimol 374–376
neurotrophic factors 377
prospects 377, 378
Iontophoresis of middle ear, spasmodic torticollis treatment 309, 310
Kaufman Brief Intelligence Test 267
Lenticular fasciculus, anatomy 22–24
Levodopa
dyskinesia induction 43, 44, 70–73, 148
history of use 10, 11, 78, 120
response and surgical outcome
prognosis 79
Macroelectrode, complication avoidance 250
Magnetic resonance imaging
evaluation of movement disorder surgery
patients 83, 87, 92, 124
gamma knife surgery planning 273, 275
non-microelectrode recording-guided
treatment with computed tomography 132, 133, 135

Subject Index
stereotactic surgery 94, 249
subthalamic nucleus stimulation 203, 205, 215
Medial forebrain bundle, anatomy 25, 26
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine brain distribution of effects 29
dyskinesia model overview 60, 61
predictions from model 62, 63
monkey model of Parkinson’s disease pathophysiology 35, 58–60
predictions from model 61, 62
problems with model clinical observations 67–70
experimental findings 63–65, 67
subthalamic nucleus stimulation of models 214
Microelectrode recording assembly of microelectrode 103, 104
complication avoidance 250, 251
instrumentation 104
overview 103
pallidotomy landmarks 105
globus pallidus external segment border cells 107
firing rates 105, 106
globus pallidus internal segment measurements 107, 108
subthalamic nucleus deep brain stimulation firing rates 109–111
landmarks 108, 109
substantia nigra 112
zona incerta 110–112
subthalamic nucleus stimulation 206
surgical technique 105
thalamotomy
Vc 113, 115
Vcpe 113, 115
Vim 112, 113, 115
Voa 113
Vop 113
Microvascular decompression, spasmodic torticollis treatment 310
Mini-Mental State Test 84

Minnesota Asberg Depression Rating Scale 87
Minnesota Multiphasic Personality Inventory 87
Muscimol globus pallidus interna inhibition 374–376
subthalamic nucleus inhibition 376
Myelotomy, spasticity treatment 344
Myotomy, spasmodic torticollis treatment 304, 305
Neural transplantation, Parkinson’s disease clinical trials 331
donor age effects 332
donor number effects 332
immunological rejection 333
longevity of graft survival 333
pathologic analysis of fetal grafts 334
positron emission tomography imaging applications 354, 355
prospects 334, 335
rationale 331
safety 334
site of transplantation 332, 333
Neuropsychological testing 87, 266–270
New Adult Reading Test – Revised 267

Pallidotomy, see also Stereotactic surgery age and outcome 125, 126
bilateral surgery 259, 260
cognition effects 268, 269
comparison with medical therapy outcomes 126
complications 127, 128, 256–260
dystonia treatment comparison to thalamotomy 291
complications 290
outcomes 287–290
technique 289, 290
evaluation of patients blinded assessment of motor function 86, 87
computed tomography 83, 92
contemporary data importance 123, 124
Pallidotomy, evaluation of patients (continued)
magnetic resonance imaging 83, 87, 92, 124
neuropsychological testing 87, 127
positron emission tomography 87, 88, 92, 93
preoperative evaluation 83
rating scales 82–85, 124
self-reporting 85, 86
timed tests 86
external segment lesion avoidance 125
gamma knife surgery 276
globus pallidus internal segment stimulation comparison 228–230
indications 121
lesion location and outcome 124, 125
microelectrode recording
globus pallidus external segment border cells 107
firing rates 105, 106
globus pallidus internal segment measurements 107, 108
landmarks 105
non-microelectrode recording-guided pallidotomy approach 136
combination of imaging modalities 132, 133, 135
complications 145
electrode placement and operation 136–138
neurological outcome
bilateral pallidotomy 141
statistical analysis 139, 141
unilateral pallidotomy 141
neuropsychological and functional outcome
bilateral pallidotomy 144
cognition 145
patient characteristics 141, 143
unilateral pallidotomy 144
outcome assessment, overview 134, 135
patient selection 133, 134
planning 135, 136
outcomes at the University of Pittsburgh 101, 102

Patient selection, see Patient selection, movement disorder surgery
positron emission tomography applications 361–364
rationale for Parkinson's disease 118–122
target localization 95, 96, 98
unilateral vs bilateral surgery 146
Panic attack, prevention in surgery 267
Parkinson's disease
akinesia/bradykinesia pathophysiology 36, 37, 59, 60
approaches for symptom treatment bradykinesia 80
dyskinesia 79, 80
tremor 80
clinical features 35
gene therapy, see Gene therapy, Parkinson's disease
 genetics 35
monkey model, see 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
muscimol therapy
globus pallidus interna 374–376
subthalamic nucleus 376
europsychological testing 87, 266–270
neurotrophic factor therapy 376, 377
nonmotor phenomena pathophysiology 39
positron emission tomography activation studies 61, 62, 367
preoperative evaluation 83
prevalence 91
rigidity pathophysiology 37, 38, 68, 69
Surgery, see also Pallidotomy, Subthalamic nucleotomy, Subthalamic nucleus stimulation, Thalamic deep brain stimulation, Thalamotomy
history of stereotactic surgery
graft injections 11, 12
lesion targets 8–10, 12
levodopa effects on popularity 10, 11
neural transplantation, see Neural transplantation, Parkinson's disease
patient selection, see Patient selection, movement disorder surgery
targets, overview 196
tremor pathophysiology 38, 39, 68, 69

Subject Index
| Parkinson’s Disease Quality-of-Life Questionnaire 86 |
| Patient selection, movement disorder surgery evaluation of patients blinded assessment of motor function 86, 87 computed tomography 83, 92 magnetic resonance imaging 83, 87, 92, 124 neuropsychological testing 87, 266–270 positron emission tomography 87, 88, 92, 93 preoperative evaluation 83 rating scales 82–85 self-reporting 85, 86 timed tests 86 exclusion criteria advanced age 81, 82, 248 alcohol abuse 81 cardiovascular conditions 93, 248 dementia 81, 248 overview 122, 123 psychiatric illness 81 severe brain atrophy or ischemia 81 terminal illness 81 typical Parkinsonism 80, 81 inclusion criteria 79, 122, 123 Pedunculopontine nucleus/midbrain extrapyramidal area akinesia role 37 lesioning 41 Peripheral neurotomy, see Selective peripheral denervation Positron emission tomography dystonia studies 282 evaluation of movement disorder surgery patients 87, 88, 92, 93 postsynaptic dopaminergic function studies D₁ ligands 357 D₂ ligands 355–357 presynaptic dopaminergic function studies applications disease progression 354 graft survival 354, 355 dopa decarboxylase 352 dopamine transporter 353 radionuclides 352–354 vesicular monoamine transporter 353, 354 regional cerebral blood flow and glucose metabolism applications activation studies hyperkinetic disorders 361 idiopathic torsion dystonia 360, 361 Parkinson’s disease 61, 62, 67, 360 differential diagnosis of Parkinson’s disease variants 357, 358 network analysis Scaled Subprofile Model 358, 359 Topographic Profile Rating 359, 360 stereotactic surgery applications deep brain stimulation 364–366 pallidotomy 361–364 thalamotomy 364 Radiofrequency lesioning, complication avoidance 252 Rhizotomy intradural rhizotomy for spasmodic torticollis treatment anatomy 315, 316 complications 321, 322 historical perspective 313, 314 outcomes 316–320, 323 technique 315, 316 spasticity treatment percutaneous thermorhizotomy 344 posterior rhizotomy 342–344 Selective peripheral denervation spasmodic torticollis treatment 310–313 spasticity treatment 340–342 Somatosensory evoked potentials, intraoperative monitoring 99 Spasmodic torticollis clinical features 296 etiology 296, 297, 300 evaluation of patients electromyography 300, 301 imaging 301 nerve blocks 301 physical examination 299, 300 incidence 296
Spasmodic torticollis (continued)
natural history 299
nonsurgical therapy
botulinum toxin type A 303, 304
pharmacotherapy 302, 303
surgery
indications 304
intratradural rhizotomy
anatomy 315, 316
complications 321, 322
historical perspective 313, 314
outcomes 316–320, 323
technique 315, 316
iontophoresis of middle ear 309, 310
microvascular decompression 310
myotomy 304, 305
selective peripheral denervation 310–313
stereotactic targets 309
thalamotomy 305, 306, 308, 309
Spasticity
nonsurgical therapy 339, 371
surgical treatment
dorsal root entry zone surgery 344–346
indications
adults 346, 347
children with cerebral palsy 347
intrathecal baclofen 339, 340, 371–374
myelotomy 344
rhizotomies
posterior rhizotomy 342–344
percutaneous thermorhizotomy 344
selective peripheral neurotomy 340–342
Spiegel-Wycis apparatus, development 4, 93
Stereotactic surgery, see also Deep brain
stimulation, Gamma knife surgery, Pallidotomy, Subthalamic nucleotomy, Thalamotomy
ablative techniques 100, 101
computed tomography 249
definition 1, 2
electrode placement 99, 100
expectations of patient 200, 262, 266
frame
application and alignment 93, 94
complications 248

Subject Index
fiber systems 22–27, 29
inactivation and movement disorder improvement 38, 188, 189
lesioning, see Subthalamic nucleotomy
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine model findings
59–62, 65, 67–74, 188, 189
muscarinic inhibition 376
projections 48
Subthalamic nucleus stimulation
comparison with other techniques advantages 220
neural grafts 217
pallidotomy 216, 217
implants 41, 42, 189
indications for deep brain stimulation 154, 189, 197
microelectrode recording during deep brain stimulation
firing rates 109–111
landmarks 108, 109
substantia nigra 112
zona incerta 110–112
motor control studies 218, 220
Parkinson's disease treatment
approach to target 214, 215
bilateral stimulation outcomes 232, 233
chronic electrode insertion 207–209
clinical evaluation 201, 202
complications 210, 211, 220, 260–262, 269
costs 216
electrical parameter setting 201, 202, 213
high-frequency stimulation effects 243
imaging and target localization 202, 203, 205, 215
long-term stability 219, 220
microelectrode insertion 206
microrecording 206, 215, 216
microstimulation 207
mortality 208, 209
patient selection factors
degree of disability 198, 199
expectations of patient 200
general health 199
magnetic resonance imaging 199
type of Parkinson's disease 197, 198
rationale of targeting 196, 197, 213, 214
single stimulus effects 242, 243
surgical technique 203, 206
unilateral vs bilateral stimulation 200
Unified Parkinson's Disease Rating Scale score outcomes 211–213
positron emission tomography applications 366
symptoms of stimulation
cognitive function effects 218
dyskinesia 217
hypophonia 217, 218
Thalamic deep brain stimulation complications 255, 256
electrode placement 184–186
frame placement 183
high-frequency stimulation effects 239, 240
indications 181, 182
macroelectrode stimulation 183
outcomes 186
patient selection 182
preoperative preparation 182, 183
safety 181, 182
single stimuli effects 237, 239
target localization 183, 184
Vim stimulation comparison with ventral thalamotomy 230–232
Thalamic fasciculus, anatomy 24
Thalamic premotor neurons, GABAergic inhibition in movement disorders 21
Thalamotomy, see also Stereotactic surgery
balancing disturbances 248
bilateral surgery 173
comparison to pallidotomy 291
complications
bilateral surgery 256
overview 254, 255
dystonia treatment complications 286, 287
outcomes 283–285
targets 283
technique 285
gait freezing 248
gamma knife surgery 275–277
Thalamotomy (continued)

historical perspective 156, 157
indications 173
meta-analysis of studies 177, 178
microelectrode recording
Vc 113, 115
Vcpc 113, 115
Vim 112, 113, 115
Voa 113
Vop 113, 167
positional emission tomography
applications 364
radiothalamotomy 169, 170
rationale for Parkinson's disease 157
spasmodic torticollis treatment 305, 306, 308, 309
Toronto Hospital experience with microelectrode recording
clinical evaluation 159, 160
complications 163, 164, 168
deep brain stimulation following failure 165, 169
failure and repeat surgery outcomes 164–167
learning curve 169
operative technique 157, 158
outcomes
comparison with other studies 168
dexterity 162, 163, 168
gait 163
speech 162, 163
technical factors affecting 160
tremor 160, 167
patient selection 157
target localization 158, 159, 169
Vim stimulation comparison 230–232
Vim thalamotomy without microelectrode recording
electrode insertion 175, 176
imaging 174
intraoperative macrostimulation 176
outcomes 177, 178
patient selection 173
radiofrequency lesion 176, 177
rationale 178, 179
target calculation 174, 175
Torticollis, see also Spasmodic torticollis
classification by etiology 298, 299
surgical management, overview 282, 283
Trail Making Test 267
Trephination, complication avoidance 249, 250
Unified Parkinson’s Disease Rating Scale
82, 84–86, 124, 126, 128, 141, 144, 146, 160, 202
Vc
anatomy 173
microelectrode recording 113, 115
Vcpc, microelectrode recording 113, 115
Ventralis intermedius nucleus, see Vim
Ventral oral anterior nucleus, see Voa
Ventral oral posterior nucleus, see Vop
Ventriculography
accuracy in brain nuclei identification 132
subthalamic nucleus stimulation 215
Ventrolateral thalamus
lesioning 41, 47, 91
stimulation, see Thalamic deep brain stimulation
Vim
anatomy 172, 173
lesioning, see Thalamotomy
microelectrode recording 112, 113, 115
stimulation for tremor treatment 148, 237
stimulation with implants 41
stimulation, see Thalamic deep brain stimulation
Visual evoked potentials, intraoperative monitoring 99, 101
Voa, microelectrode recording 113
Vop, microelectrode recording 113, 167
Wechsler Adult Intelligence Scale 267